Telomir Pharmaceuticals sees breakthrough potential in Anti-Aging Treatment with Telomir 1
Vancouver, Canada
|
May 07, 2024 03:02 PM Eastern Daylight Time
Telomir Pharmaceuticals Co-Founder Frank O’Donnell joined Steve Darling from Proactive to share what the company believe is groundbreaking potential of their new drug designed to extend telomeres, which could reverse aging and age-related diseases. During a recent interview, O'Donnell elaborated on the drug’s potential, supported by extensive research in mice and successful trials in larger animals like a German shepherd.
Drawing from his background in ophthalmology at Johns Hopkins, O'Donnell explained that the drug is developed to fight conditions such as macular degeneration by manipulating telomeres—protective caps on chromosomes that degrade over time. This innovative approach has shifted the company's focus from merely prolonging life to actively reversing signs of aging.
O'Donnell also touched on the drug’s promising implications for veterinary medicine, particularly its potential benefits for older dogs suffering from osteoarthritis. Upcoming studies on dogs are planned to further prove the drug's effectiveness before moving to human clinical trials slated to begin in January 2025.
Emphasizing the drug's transformative capabilities, O'Donnell spoke of its potential global impact by rejuvenating biological clocks and enhancing overall health. Currently, Telomir Pharmaceuticals is not seeking additional funding, opting instead to focus on advancing their research and commencing significant clinical trials.
Contact Details
Proactive North America
+1 604-688-8158
